NEXTRACKER
14.3.2023 07:04:42 CET | Business Wire | Press release
Nextracker Inc. (NASDAQ: NXT) secured a new deal in Europe for its terrain-following solar tracker NX Horizon-XTR™ (XTR), demonstrating demand for tracking technology that enables solar developers to build on land with complex topography and unique environmental constraints. The German international solar developer, IbVogt, chose Nextracker’s XTR for the 150 MW Garnacha solar power plant in Spain. The project is backed by a 12-year power purchase agreement (PPA) with Google and is expected to begin production October of 2023. Leading the global market in solar trackers and optimization software, Nextracker’s advanced technology systems allow solar panels to follow the sun’s movement and maximize energy output.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230313005879/en/
European Renewable Energy Developer IbVogt chooses Nextracker’s NX Horizon-XTR for its upcoming 150 MW project in Spain (Photo: Business Wire)
“Due to the local zero grading requirements on our project, we needed a solar tracker solution that would have minimal environmental impact and allow us to secure local permits,“ stated Patrick Zenker, Global Procurement Director of IbVogt. ” With a 10-gigawatt track record, NX Horizon-XTR gave us peace of mind and low risk."
“With gas price volatility, European leaders are looking for the lowest cost, most reliable form of energy, and that is utility scale solar power,” said Dan Shugar, Founder and CEO of Nextracker. “Europe’s exceptional environmental stewardship, unique cultural sites and challenging topography provide the perfect conditions for our terrain-following trackers that maximize energy output with a light-on-land footprint.”
Nextracker’s NX Horizon-XTR™ allows rows of solar panels to adjust to uneven terrain, following the natural curvature of the earth. Its terrain-following capabilities enable developers to work on challenging sites that would otherwise be infeasible. It also cuts costs by limiting grading work and associated delays, simplifying the permitting process, and reducing the need for soil-related maintenance.
Solar projects using NX Horizon-XTR have a lighter impact on the environment as they leave more soil intact, benefitting the local ecology and reducing risk of soil erosion. The projects also require less steel for extended pilings, lowering a project’s overall carbon footprint.
The Garnacha project expands Nextracker’s multi-gigawatt portfolio in Europe. The company has offices in Seville and Madrid, with dedicated employees working with customers across the continent with deep expertise to support the life cycle of every project.
“The Nextracker European team has achieved an important milestone of reaching over 3 GW of projects with major solar developers, utilities and European EPC companies for projects in Europe as well as Brazil, USA, Canada and Africa,” said Arturo Herrero, Nextracker SVP Europe.
Nextracker, a leading solar tracking company with 70 GW shipped globally to five continents, has deployed their terrain-following NX-Horizon XTR on close to 10 GW of utility-scale solar globally. Nextracker’s solar trackers increase energy production by 20-30% more than fixed-tilt applications that do not track the sun.
About Nextracker
Nextracker is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and ground-mounted distributed generation solar projects around the world. Our products enable solar panels in utility-scale power plants to follow the sun’s movement across the sky and optimize plant performance. With more than 70 gigawatts shipped worldwide, Nextracker offers solar tracker technologies that optimize and increase energy production while reducing costs for significant plant ROI. For more information, please visit Nextracker.
Stay in touch with us: Twitter LinkedIn Instagram Facebook
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005879/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom